Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT
- PMID: 24652232
- DOI: 10.1007/s00259-014-2744-4
Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT
Abstract
Purpose: Imaging biomarkers from functional imaging modalities were assessed as potential surrogate markers of disease status. Specifically, in this prospective study, we investigated the relationships between functional imaging parameters and histological prognostic factors and breast cancer subtypes.
Methods: In total, 43 patients with large or locally advanced invasive ductal carcinoma (IDC) were analyzed (47.6 ± 7.5 years old). (68)Ga-Labeled arginine-glycine-aspartic acid (RGD) and (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were performed. The maximum and average standardized uptake values (SUVmax and SUVavg) from RGD PET/CT and SUVmax and SUVavg from FDG PET/CT were the imaging parameters used. For histological prognostic factors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression was identified using immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). Four breast cancer subtypes, based on ER/PR and HER2 expression (ER/PR+,Her2-, ER/PR+,Her2+, ER/PR-,Her2+, and ER/PR-,Her2-), were considered.
Results: Quantitative FDG PET parameters were significantly higher in the ER-negative group (15.88 ± 8.73 vs 10.48 ± 6.01, p = 0.02 for SUVmax; 9.40 ± 5.19 vs 5.92 ± 4.09, p = 0.02 for SUVavg) and the PR-negative group (8.37 ± 4.94 vs 4.79 ± 3.93, p = 0.03 for SUVavg). Quantitative RGD PET parameters were significantly higher in the HER2-positive group (2.42 ± 0.59 vs 2.90 ± 0.75, p = 0.04 for SUVmax; 1.60 ± 0.38 vs 1.95 ± 0.53, p = 0.04 for SUVavg) and showed a significant positive correlation with the HER2/CEP17 ratio (r = 0.38, p = 0.03 for SUVmax and r = 0.46, p < 0.01 for SUVavg). FDG PET parameters showed significantly higher values in the ER/PR-,Her2- subgroup versus the ER/PR+,Her2- or ER/PR+,Her2+ subgroups, while RGD PET parameters showed significantly lower values in the ER/PR-,Her2- subgroup versus the other subgroups. There was no correlation between FDG and RGD PET parameters in the overall group. Only the ER/PR-,Her2- subgroup showed a significant positive correlation between FDG and RGD PET parameters (r = 0.59, p = 0.03 for SUVmax).
Conclusion: (68)Ga-RGD and (18)F-FDG PET/CT are promising functional imaging modalities for predicting biomarkers and molecular phenotypes in breast cancer patients.
Comment in
-
Mismatch between perfusion and metabolism in locally advanced breast cancer.Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):803-4. doi: 10.1007/s00259-014-2931-3. Epub 2014 Oct 15. Eur J Nucl Med Mol Imaging. 2015. PMID: 25316297 No abstract available.
Similar articles
-
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226. Cancer. 2008. PMID: 18098228 Clinical Trial.
-
Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.World J Surg Oncol. 2015 Mar 15;13:113. doi: 10.1186/s12957-015-0522-9. World J Surg Oncol. 2015. PMID: 25889560 Free PMC article.
-
Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.Nucl Med Commun. 2015 Jan;36(1):28-37. doi: 10.1097/MNM.0000000000000217. Nucl Med Commun. 2015. PMID: 25299471
-
Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates.Pathobiology. 2022;89(5):263-277. doi: 10.1159/000525092. Epub 2022 Jun 21. Pathobiology. 2022. PMID: 35728576 Review.
-
Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?Reprod Biol Endocrinol. 2025 Jan 20;23(1):9. doi: 10.1186/s12958-024-01338-z. Reprod Biol Endocrinol. 2025. PMID: 39833837 Free PMC article. Review.
Cited by
-
Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence.EJNMMI Res. 2021 Apr 12;11(1):37. doi: 10.1186/s13550-021-00776-9. EJNMMI Res. 2021. PMID: 33846870 Free PMC article.
-
EDB-FN-targeted probes for near infrared fluorescent imaging and positron emission tomography imaging of breast cancer in mice.Sci Rep. 2024 Sep 27;14(1):22056. doi: 10.1038/s41598-024-73362-3. Sci Rep. 2024. PMID: 39333775 Free PMC article.
-
[(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma.Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):654-62. doi: 10.1007/s00259-015-3219-y. Epub 2015 Oct 22. Eur J Nucl Med Mol Imaging. 2016. PMID: 26490751
-
Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis.Sci Rep. 2017 May 8;7(1):1556. doi: 10.1038/s41598-017-01524-7. Sci Rep. 2017. PMID: 28484211 Free PMC article.
-
KSNM60: The History of Radiopharmaceutical Sciences in Korea.Nucl Med Mol Imaging. 2022 Jun;56(3):114-126. doi: 10.1007/s13139-022-00744-8. Epub 2022 Apr 5. Nucl Med Mol Imaging. 2022. PMID: 35607629 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous